A partially paralyzed CEO brings a dogged approach to researching a novel treatment for spinal cord injuries. Up next: human trials.READ MORE›
ADVERTISEMENT
Share on StumbleUpon
Share on LinkedIn
Share on StumbleUpon
Share on LinkedIn